MENA CVD Orbuculum

The incidence of atrial fibrillation (AF) in the Middle East and North Africa (MENA) region varies depending on the specific country and population studied. However, overall, the incidence of AF in the MENA region is thought to be relatively high. Studies have found that the prevalence of AF in the

The incidence of extracranial carotid artery disease (ECAD) in the Middle East and North Africa (MENA) region is thought to be relatively high. Studies have found that the prevalence of ECAD in the MENA region ranges from 5-20%. Factors that contribute to the high incidence of ECAD in the MENA

The incidence and prevalence of metabolic syndrome (MetS) in the Middle East and North Africa (MENA) region is considered high. Studies have found that the prevalence of MetS in the MENA region ranges from 20-40%. Factors that contribute to the high incidence of MetS in the MENA region include increasing

The incidence and prevalence of hypertension (high blood pressure) in the Middle East and North Africa (MENA) region is considered high. Studies have found that the prevalence of hypertension in the MENA region ranges from 20-50%. Factors that contribute to the high incidence of hypertension in the MENA region include

The incidence of stroke in young individuals (defined as those below the age of 45 or 50) in the Middle East and North Africa (MENA) region is not extensively studied, and data specific to the region may be limited. However, there is some evidence suggesting that the incidence of stroke

Affecting about 800,000 people yearly and the leading cause of death and disability in the United States, acute ischemic stroke (AIS) accounts for almost 87% of all strokes and remains an area of high unmet medical need. While several therapeutic options are available to patients, each has its limitations, including narrow therapeutic windows, risk of bleeding, and accessibility issues.

Developing new treatments for acute ischemic stroke that can quickly and safely intervene at the right place and time has been a particularly challenging endeavor characterized by a graveyard of clinical trial failures since the early 2000s. However, today the situation is changing due to technological developments related to stroke and recent advances in RNA-based medicines.

The Limitations Of Current Treatments For Acute Ischemic Stroke
Tissue plasminogen activator (tPA) is a clot-dissolving medicine approved in 1996 by the U.S. FDA to treat acute ischemic stroke. Unfortunately, tPA has several drawbacks that limit its clinical usage. These include its narrow therapeutic window of 3 to 4.5 hours, potential complications with IV administration, and a high risk of bleeding into the brain (hemorrhages), which due to a lack of reversibility is the most severe complication of treatment, limiting its usefulness for the majority of stroke patients.

A newer treatment option for patients with acute ischemic stroke is endovascular thrombectomy (EVT), a minimally invasive surgical procedure that use

MUNICH — Giving intensive statin therapy to patients with acute mild ischemic stroke or with high-risk for transient ischemic attack (TIA) immediately after onset significantly reduces the risk for a poor functional outcome compared with delaying treatment, without compromising safety, results of the INSPIRES trial show. The research, presented at the 9th European Stroke Organisation Conference

MUNICH — Patients undergoing carotid artery stenting (CAS) may have fewer ischemic lesions and a lower lesion burden if they are given the reversible P2Y12 receptor antagonist ticagrelor rather than clopidogrel, another P2Y12 inhibitor, prior to the procedure, secondary endpoint results of the PRECISE-MRI trial suggest. More than 200 patients with carotid artery stenosis underwent magnetic resonance

MUNICH — Anticoagulation using apixaban (Eliquis) offers no benefit over aspirin in patients with embolic stroke of undetermined source (ESUS) who have atrial cardiopathy but no overt atrial fibrillation, suggest findings from the ARCADIA trial. The trial, which was halted early, randomized more than 1000 ESUS patients with atrial cardiomyopathy to apixaban or placebo. Results showed

MUNICH — A multidisciplinary post-stroke care program failed to show a reduction in hard clinical endpoints over standard care after 1 year of follow-up, a new study shows, although it did achieve improvements in cardiovascular risk-related measures. Experts argued that the trial, presented at the European Stroke Organisation Conference (ESOC)